Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC3020
Trial ID NCT05359211
Disease Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Primary Mediastinal B-Cell Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017
Co-treatment NKTR-255
Location approved US, Japan, EU, Switzerland, UK, Canada
Generation2nd
PhasePhase1
Recruitment statusRecruiting
TitleNKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Year2022
CountryUnited States
Company sponsorFred Hutchinson Cancer Center
Other ID(s)RG1122036|NCI-2022-02316|10802
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneanti‐CD19 single‐chain variable fragment; 4‐1BB costimulatory motif; CD3ζ T‐cell activation domain
Additional featureEGFRt

Clinical Result

Cohort 1
Administration route intravenous infusion
Donor type Autologous
Pts 24
Age Adult, Older_Adult
Lymph depletion Yes

Relationship Graph

Overview of Knowledge Graph